SoylentNews

fork(2) [soylentnews.org] writes:

      Want to stay/get younger? Inject plasma from a younger person...

      Now a startup has launched a "clinical trial" to test the antiaging benefits of such treatment...but it's pay-per-view. Writing in Science today, Jocelyn Kaiser reports on the ethical, and other, aspects of this project. From her article, "Young blood antiaging trial raises questions [sciencemag.org]":

[...] The company, Ambrosia in Monterey, California, plans to charge participants $8000 for lab tests and a one-time treatment with young plasma. The volunteers don't have to be sick or even particularly aged--the trial is open to anyone 35 and older. Karmazin notes that the study passed ethical review and argues that it's not that unusual to charge people to participate in clinical trials.

      To some ethicists and researchers, however, the trial raises red flags, both for its cost to participants and for a design that they say is unlikely to deliver much science. "There's just no clinical evidence [that the treatment will be beneficial], and you're basically abusing people's trust and the public excitement around this," says neuroscientist Tony Wyss-Coray of Stanford University in Palo Alto, California, who led the 2014 young plasma study in mice. [In which injecting old mice with the plasma portion of blood from young mice seemed to improve the elderly rodents' memory and ability to learn.]

      [...]

      To bioethicist Leigh Turner at the University of Minnesota, Twin Cities, the study brings to mind a growing number [washingtonpost.com] of scientifically dubious trials registered in ClinicalTrials.gov by private, for-profit stem cell clinics. The presence of such trials in the database confers "undeserved legitimacy," he says.

      The scientific design of the trial is drawing concerns as well. "I don't see how it will be in any way informative or convincing," says aging biologist Matt Kaeberlein of the University of Washington, Seattle. The participants won’t necessarily be elderly, making it hard to see any effects, and there are no well-accepted biomarkers of aging in blood, he says. "If you're interested in science," Wyss-Coray adds, why doesn't such a large trial include a placebo arm? Karmazin says he can't expect people to pay knowing they may get a placebo. With physiological measurements taken before and after treatment, each person will serve as their own control, he explains.

Original Submission